ATHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Athira Pharma's goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil.
The historical data trend for Athira Pharma's Goodwill can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
Athira Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Goodwill | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Athira Pharma (NAS:ATHA) Goodwill Explanation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Athira Pharma's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Goodwill-to-Asset (A: Dec. 2024 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 58.779 | |
= |
Athira Pharma's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Goodwill-to-Asset (Q: Dec. 2024 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 58.779 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Athira Pharma's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark James Litton | officer: Chief Operating Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Mark Worthington | officer: General Counsel | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Kevin Church | officer: Vice President of Discovery | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Rachel Lenington | officer: Chief Technology Officer | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Andrew Gengos | officer: See Below | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Kelly A Romano | director | C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Grant Pickering | director | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
James A Johnson | director | C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102 |
Glenna Mileson | officer: Chief Financial Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Hans Moebius | officer: Chief Medical Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Michael A. Panzara | director | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Barbara Kosacz | director | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
From GuruFocus
By Marketwired • 12-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 09-03-2024
By Marketwired • 04-15-2024
By Marketwired • 07-09-2024
By GlobeNewswire • 12-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-29-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.